Greg Hanson Email & Phone Number

Southeastern US

* Help residents in long term care ICF/IID facilities with rare epilepsy conditions. * Identify and develop opportunities to help sales representatives succeed.* Work with top regional and state ICF/IDD group home chains. * Interact with National GPO accounts, pharmacy directors, independent pharmacy providers, and consultant pharmacist groups. * Work with.

Greater Tampa Bay Area

Began Regional Trainer role in 1/22.Promoted to Senior Specialty Sales Consultant in 1/23.

Tampa/St. Petersburg, Florida Area

Sold Xyrem - launched Xywav and Sunosi to Sleep Specialists, Pulmonologists, Neurologists, Psychiatrists and other health care providers.Annual ranking summary: 2022: 14/72; 2021: 9/73; 2020: 19/132; 2019: 8/21.Attained national rank of 3/73 for YTD Xywav prescriptions in 2021.Attained 6th most YTD Xywav prescriptions out of 73 territories.Lone SSC out of.

Tampa/St. Petersburg, Florida Area

• Bio-pharmaceutical company focused on acquiring and marketing CNS products to treat un-met needs. Launched Onzetra to neurologists and primary care physicians.
• Annual ranking summary: 2018: 33/100; 2017: 133/217; 2016: 66/220; 2015: 41/71.
• Invited to participate on the 2017 Nuedexta SMAC (field advisory) team.
• Selected to represent the Southeastern US on the 2016 Onzetra field advisory board.

Naples, Fort Myers, Sarasota, St. Petersburg And Tampa Florida Area

• Launched Nuedexta to neurologists, psychiatrists, primary care and LTC providers.
• Annual ranking summary: 2014: 10/71; 2013: 21/71; 2012: 15/73; 2011: 44/76.
• Exceeded 2012 annual bonus target with one quarter of sales performance.
• Grew volume from 127 prescriptions in 2011 to 1,300 in 2012.

Tampa/St. Petersburg, Florida Area

• Private pharmaceutical company focused on acquiring amd marketing mature prescription products for the U.S. psychiatry market.Re-launched and sold Equetro and Marplan to psychiatrists and NPs/PAs in Central Florida.
• Achieved annual ranking of #2 in 2010.
• Created new territory marketing plan and quickly improved prescription trends.
• Successfully convinced psychiatrists to prescribe Equetro over generic Carbamazepine and other branded mood stabilizers.

• Launched Symbicort and other respiratory products to specialists in the Tampa Bay area.
• Annual ranking summary: 2008: 3/43; 2007: 31/43.
• Developed and implemented strategic marketing plan to gain market share from a competitor that had a six-year head start.
• One of four in the country to receive the 2008 Symbicort Summit Award for driving market share over 30%.
• Generated 169% of YTD goal within the first six months of launch in 2007.

Tampa/St. Petersburg, Florida Area

• Launched Crestor and Nexium to cardiovascular and GI specialists. Managed key account selling to over-achieve sales goals. Designed and facilitated in-service presentations to train sales representatives, physicians.
• Increased calls and sales in targeted accounts by 84%, which earned me the rank of #1 in the nation.
• Obtained five consecutive annual performance ratings of excellent. Utilized excellent leadership and communication skills in working with sales and marketing teams to improve sales representative effectiveness.
• Created and delivered three regional marketing research programs within 6 months. Partnered with regional leadership, compliance and legal to get programs approved.

Birmingham, Alabama Area

• Successfully launched Rhinocort, Rhinocort Aqua, Pulmicort Turbuhaler and Pulmicort Respules to respiratory specialists and primary care physicians. Managed, coached and led nine sales representatives to achieve their.
• Over-achieved district annual sales goals from 1994 through 1999. Effectively allocated coaching visits and resources to team. Worked with best representatives to learn how lower performers could improve.
• Successfully managed four respiratory product launches. Designed and coordinated unique and successful customer programs to drive market share with key accounts.

Greater Grand Rapids, Michigan Area

• One of 70 in a new sales force that launched Toprol-XL, a cardiovascular medication. Successfully achieved portfolio sales goals across a large rural territory.
• Attained #10 regional ranking. Developed specialists and primary care physicians into advocates through effective planning and selling.
• Achieved 179% of national market share average. Focused efforts on physicians in top areas to develop a 41% market share in key zip codes.
• Reached YTD share of 11% in first year of launch.